International Stem Cell Corp (ISCO) — SEC Filings
International Stem Cell Corp (ISCO) — 13 SEC filings. Latest: 8-K (Nov 18, 2025). Includes 6 10-Q, 3 8-K, 2 DEF 14A.
View International Stem Cell Corp on SEC EDGAR
Overview
International Stem Cell Corp (ISCO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 18, 2025: International Stem Cell Corporation filed an 8-K on November 18, 2025, reporting on events that occurred on June 17, 2025. The filing pertains to a submission of matters to a vote of security holders. The company, formerly known as BTHC III INC., is incorporated in Delaware and headquartered in San
Sentiment Summary
Across 13 filings, the sentiment breakdown is: 2 bearish, 11 neutral. The dominant filing sentiment for International Stem Cell Corp is neutral.
Filing Type Overview
International Stem Cell Corp (ISCO) has filed 3 8-K, 6 10-Q, 2 DEF 14A, 2 10-K with the SEC between Mar 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (13)
Risk Profile
Risk Assessment: Of ISCO's 13 recent filings, 2 were flagged as high-risk, 9 as medium-risk, and 2 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $2.369 million |
| Net Income | $57 thousand |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $966 thousand |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Andrey Semechkin, PhD
Industry Context
The stem cell industry is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies in this sector often operate at a loss for extended periods due to these factors. Competition is intense, with both established biotechnology firms and emerging startups vying for market share and investment.
Top Tags
10-Q (4) · pharmaceuticals (3) · financials (3) · Biotechnology (2) · Stem Cell Research (2) · Going Concern (2) · financial-obligation (2) · 10-K (2) · ISCO (2) · corporate-governance (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net income | $57 thousand | for the three months ended September 30, 2025, compared to a $125 thousand net loss in Q3 2024 |
| Product sales | $2.369 million | for the three months ended September 30, 2025, an 8.7% increase from $2.179 million in Q3 2024 |
| Net loss | $70 thousand | for the nine months ended September 30, 2025, a reduction from $220 thousand in the prior year |
| Accumulated deficit | $110.755 million | as of September 30, 2025, indicating significant historical losses |
| Cash on hand | $966 thousand | as of September 30, 2025, a decrease of $264 thousand from the beginning of the period |
| Related party note payable | $3.305 million | as of September 30, 2025, a slight decrease from $3.395 million at December 31, 2024 |
| Net cash used in operating activities | $24 thousand | for the nine months ended September 30, 2025, indicating negative operational cash flow |
| Common Stock outstanding | 8,004,389 | as of November 7, 2025 |
| Accumulated Deficit | $110.8M | Indicates significant historical losses and contributes to going concern risk. |
| Cash on Hand | $920K | Insufficient to sustain operations for 12 months, highlighting liquidity issues. |
| Six-Month Net Loss | $127K | Widened from $95K in prior year, showing continued unprofitability. |
| Three-Month Net Income | $129K | A positive, but small, quarterly profit amidst overall H1 loss. |
| Six-Month Product Sales | $4.576M | Slight increase from $4.460M, indicating modest revenue growth. |
| Q2 Research & Development Expense | $162K | Increased significantly from $83K, reflecting higher investment in R&D. |
| Net Cash Used in Operating Activities (H1) | $73K | Company continues to burn cash from operations. |
Frequently Asked Questions
What are the latest SEC filings for International Stem Cell Corp (ISCO)?
International Stem Cell Corp has 13 recent SEC filings from Mar 2024 to Nov 2025, including 6 10-Q, 3 8-K, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ISCO filings?
Across 13 filings, the sentiment breakdown is: 2 bearish, 11 neutral. The dominant sentiment is neutral.
Where can I find International Stem Cell Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all International Stem Cell Corp (ISCO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for International Stem Cell Corp?
Key financial highlights from International Stem Cell Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ISCO?
The investment thesis for ISCO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at International Stem Cell Corp?
Key executives identified across International Stem Cell Corp's filings include Andrey Semechkin, PhD.
What are the main risk factors for International Stem Cell Corp stock?
Of ISCO's 13 assessed filings, 2 were flagged high-risk, 9 medium-risk, and 2 low-risk.
What are recent predictions and forward guidance from International Stem Cell Corp?
Forward guidance and predictions for International Stem Cell Corp are extracted from SEC filings as they are enriched.